DSM Nutritional Products, Wurmisweg 576, 4303 Kaiseraugst, Switzerland.
ProDigest, Technologiepark 82, Zwijnaarde, 9052 Ghent, Belgium.
Nutrients. 2023 Mar 28;15(7):1637. doi: 10.3390/nu15071637.
Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) cause intestinal discomfort in patients with irritable bowel syndrome (IBS). An enzyme mix (2500 SU invertase, 2400 GalU α-galactosidase, 10,000 ALU β-galactosidase) optimized for FODMAP digestion, and/or human milk oligosaccharides (HMO) (2'-FL, DFL, and LNnT), were evaluated for effects on microbial community activity and composition in short-term colonic incubations using the fecal microbiota of four patients with IBS-D symptoms under the following test conditions: (i) FODMAP, (ii) pre-digested (with enzyme mix) FODMAP, (iii) FODMAP + HMO, and (iv) pre-digested FODMAP + HMO. Pre-digested FODMAP reduced short-chain fatty acid (SCFA) production versus FODMAP; HMO restored this. A 10-day experiment with the simulator of the human intestinal microbial ecosystem (SHIME), using fecal samples from two patients with IBS-D, further evaluated these findings. FODMAP resulted in decreased microbial diversity versus blank. Pre-digestion with the enzyme mix restored microbial diversity, improved FODMAP digestibility, and reduced gas pressure versus undigested FODMAP; however, SCFA production decreased. HMO restored SCFA production along with an increase in gas pressure and increased abundance of . When used in combination, the FODMAP enzyme mix and HMO may resolve FODMAP-related IBS symptoms while maintaining a healthy gut microbiome via prebiotic activity.
可发酵的寡糖、双糖、单糖和多元醇（FODMAPs）会引起肠易激综合征（IBS）患者的肠道不适。一种针对 FODMAP 消化优化的酶混合物（2500SU 转化酶、2400GalUα-半乳糖苷酶、10000ALUβ-半乳糖苷酶）和/或人乳寡糖（HMO）（2'-FL、DFL 和 LNnT），在以下测试条件下用于评估对短期结肠孵育中微生物群落活性和组成的影响：（i）FODMAP，（ii）预消化（用酶混合物）FODMAP，（iii）FODMAP+HMO，和（iv）预消化 FODMAP+HMO。与 FODMAP 相比，预消化 FODMAP 降低了短链脂肪酸（SCFA）的产生；HMO 恢复了这一点。使用来自两名 IBS-D 患者的粪便样本进行为期 10 天的人类肠道微生物生态系统模拟器（SHIME）实验，进一步评估了这些发现。与空白相比，FODMAP 导致微生物多样性降低。用酶混合物进行预消化恢复了微生物多样性，提高了 FODMAP 的消化率，并降低了未消化 FODMAP 的气体压力；然而，SCFA 的产生减少了。HMO 恢复了 SCFA 的产生，同时增加了气体压力，并增加了. 的丰度。当组合使用时，FODMAP 酶混合物和 HMO 可能会解决与 FODMAP 相关的 IBS 症状，同时通过益生元活性维持健康的肠道微生物组。
